A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112

Phase 1

Completed

• Conditions: Obesity
• Interventions: Drug: Placebo; Drug: HSG4112

• Registration Number: NCT04732988
• Lead Sponsor: Glaceum

Brief Summary

1. Study Objective: The objective of this phase 1 clinical trial is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and food effect of HSG4112 after oral administration in healthy male subjects.

2. Study Design and Plan: This study is a dose-block randomized, double-blind, placebo-controlled, single and multiple dosing, dose-escalation phase 1 clinical trial. A unique randomization number will be assigned to each subject deemed eligible to participate in the study based on the inclusion/exclusion criteria. Each subject will be randomized to one of the six groups for the single ascending dose (SAD) study or one of the three groups for the multiple ascending dose (MAD) study. Each dose group will consist of ten subjects, and among the ten subjects, eight subjects will be randomized to receive HSG4112 and two subjects will be randomized to receive placebo. The subjects will be studied in a double-blind manner and will receive the investigational product (i.e., HSG4112 or placebo) via once-daily oral administration. The dosing duration for the MAD study is 14 days. When escalating the dose, the Investigator will review all of the available safety data from the preceding dose in a blinded manner to ensure if it is safe to escalate the dose. In order to evaluate safety and tolerability, assessments, such as vital signs, 12-lead electrocardiogram, laboratory test, semen analysis (MAD study only), physical examination, and adverse event monitoring will be performed. Blood samples will be collected to evaluate the pharmacokinetic/pharmacodynamic characteristics of HSG4112.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-08-23
• Study First Submitted: 2021-01-19
• Study First Submitted QC: 2021-01-29
• Study First Posted: 2021-02-01
• Primary Completion: 2021-05-24
• Study Completion: 2021-05-24
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-25
• Last Update Posted: 2021-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 90

Inclusion Criteria

1. Able to comprehend and willing to sign an informed consent form approved by the IRB before screening.

2. Males between 19 and 50 years of age at screening.

3. Body mass index (BMI) between 18 and 24.9.

   ☞ BMI (kg/m2) = Body weight (kg) / {Height (m)2}

4. In good health, determined by no clinically significant findings from medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory test at screening, or subjects who are deemed acceptable by the Investigator regardless of the test results.

Read More

Exclusion Criteria

1. Significant history or clinical manifestation of any hepatic, kidney, neurological, immune, respiratory, endocrine, hematological, neoplastic, or cardiovascular disease, or psychiatric disorder (e.g., mood disorder, obsessive-compulsive disorder).

2. History of stomach or intestinal disorders (e.g., Chrons disease, ulcer) or surgeries - not including appendectomy, hemorrhoidectomy, or herniotomy - which may affect the pharmacokinetic or pharmacodynamic evaluation of the investigational product.

3. Significant history or clinical manifestation of hypersensitivity to any drug compound (e.g., licorice, aspirin, antibiotics).

4. One of more of the following laboratory test results at screening:

   • ALT (SGPT) > 60 IU/L
   • Glucose (fasting) > 110 mg/dL or < 70 mg/dL
   • Testosterone <2.49 ng/mL or > 8.36 ng/mL

5. Systolic blood pressure of < 90 mmHg or > 150 mmHg, or diastolic blood pressure of < 60 mmHg or > 100 mmHg as determined by vital signs monitored after resting in sitting position for at least 3 minutes.

6. History of drug/chemical abuse or tested positive in urine drug screen.

7. Use or intend to use any prescription medications/products or phytotherapeutic/herbal/plant-derived preparations within 14 days prior to dosing, or any nonprescription medications/products (i.e., over-the-counter (OTC) drugs), health products, or vitamins within 7 days prior to dosing, unless deemed acceptable by the Investigator.

8. Participation in any clinical study or bioequivalence study involving administration of an investigational drug, including any study investigating HSG4112, within 6 months prior to dosing (i.e., within 6 months of the last dose from the previous study).

9. Whole blood donation within 2 months prior to dosing, plasma/platelet donation within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing.

10. Alcohol consumption of > 20 units/week (1 unit = 10 g of pure alcohol) or unable to abstain from consuming alcohol during the study period.

11. Smoked within 90 days prior to dosing. However, participation is acceptable if the subject has quit smoking at least 90 days prior to dosing.

12. Smoker. However, participation is acceptable if the subject has quit smoking at least 3 months prior to dosing.

13. Ingestion of grapefruit-containing foods or beverages 24 hours prior to dosing until discharge, or unable to abstain from ingesting such foods or beverages during the same period.

14. Unable to abstain from caffeine-containing foods or beverages (e.g., coffee, tea (e.g., black tea, green tea), soft drinks, coffee milk, energy drinks, sports drinks) during the admission period.

15. Unable or unwilling to use acceptable contraceptive methods during the study period.

    ☞ Acceptable contraceptive methods include:

    • Use of an intrauterine device, which has been proven highly effective, by the subject's spouse/partner.
    • Physical contraception for subject or spouse/partner used with chemical sterilization.
    • Surgical sterilization (e.g., vasectomy, hysterectomy, tubal ligation, salpingectomy) of the subject or the subject's spouse/partner.

16. Subjects who, in the opinion of the Investigator, should not participate in this study based on clinical laboratory test results or other reasons.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo 480 mg Single Dose	Placebo	Single oral dosing of Placebo 480 mg
Placebo 480 mg Multiple Dose	Placebo	Once-daily multiple oral dosing of Placebo 480 mg for 14 days
HSG4112 60 mg Single Dose	HSG4112	Single oral dosing of HSG4112 60 mg
Placebo 60 mg Single Dose	Placebo	Single oral dosing of Placebo 60 mg
HSG4112 480 mg Single Dose	HSG4112	Single oral dosing of HSG4112 480 mg
HSG4112 240 mg Single Dose (Fed)	HSG4112	Single oral dosing of HSG4112 240 mg under fed conditions
HSG4112 30 mg Single Dose	HSG4112	Single oral dosing of HSG4112 30 mg
HSG4112 120 mg Single Dose	HSG4112	Single oral dosing of HSG4112 120 mg
Placebo 120 mg Single Dose	Placebo	Single oral dosing of Placebo 120 mg
HSG4112 240 mg Single Dose (Fasted)	HSG4112	Single oral dosing of HSG4112 240 mg under fasted conditions
Placebo 240 mg Single Dose	Placebo	Single oral dosing of Placebo 240 mg
HSG4112 720 mg Single Dose	HSG4112	Single oral dosing of HSG4112 720 mg
Placebo 30 mg Single Dose	Placebo	Single oral dosing of Placebo 30 mg
Placebo 720 mg Single Dose	Placebo	Single oral dosing of Placebo 720 mg
Placebo 240 mg Multiple Dose	Placebo	Once-daily multiple oral dosing of Placebo 240 mg for 14 days
HSG4112 240 mg Multiple Dose	HSG4112	Once-daily multiple oral dosing of HSG4112 240 mg for 14 days
HSG4112 480 mg Multiple Dose	HSG4112	Once-daily multiple oral dosing of HSG4112 480 mg for 14 days

Primary Outcome Measures

Name	Time	Method
Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112	Hour 0 to 192	Maximum plasma concentration of HSG4112 (Cmax)
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point	Hour 0 to 192	Area under the plasma concentration-time curve from time zero to the last measurable point (AUClast)
Safety and Tolerability Assessment by Number of Patients with Change in Physical Examination	Up to 3 weeks from day of last dosing	Number of participants with clinically significant change in physical examination
Safety and Tolerability Assessment by Number of Patients with Change in Semen Volume	Up to 12 weeks from day of last dosing	Pre-to-post examination of semen volume (milliliters) by semen analysis to assess the safety and tolerability of HSG4112
Safety and Tolerability Assessment by Number of Patients with Change in Semen White Blood Cells	Up to 12 weeks from day of last dosing	Pre-to-post examination of semen white blood cells (10\^3 per microliter) by semen analysis to assess the safety and tolerability of HSG4112
Safety and Tolerability Assessment by Number of Patients with Change in Sperm Count	Up to 12 weeks from day of last dosing	Pre-to-post examination of sperm count (10\^6 per milliliter) by semen analysis to assess the safety and tolerability of HSG4112
Safety and Tolerability Assessment by Number of Patients with Change in Sperm Morphology	Up to 12 weeks from day of last dosing	Pre-to-post examination of sperm morphology (percent of normal sperm) by semen analysis to assess the safety and tolerability of HSG4112
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval	Hour 0 to 24	Area under the plasma concentration-time curve of HSG4112 over dosing interval (AUCtau)
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity	Hour 0 to 192	Area under the plasma concentration-time curve from time zero to infinity (AUCinf)
Safety and Tolerability Assessment by Number of Patients with Change in Sperm Motility	Up to 12 weeks from day of last dosing	Pre-to-post examination of sperm motility (percent of sperm with normal motility) by semen analysis to assess the safety and tolerability of HSG4112
Pharmacokinetic Assessment by Half-Life of HSG4112	Hour 0 to 192	Half-life of HSG4112 (T1/2)
Safety and Tolerability Assessment by Number of Participants with Change in Laboratory Test	Up to 3 weeks from day of last dosing	Number of participants with clinically significant change in laboratory test assessed through hematology, blood biochemistry, urinalysis, and blood coagulation test
Safety and Tolerability Assessment by Number of Patients with Change in Semen pH	Up to 12 weeks from day of last dosing	Pre-to-post examination of semen white blood cells (10\^3 per microliter) by semen analysis to assess the safety and tolerability of HSG4112
Pharmacokinetic Assessment by Oral Clearance of HSG4112	Hour 0 to 192	Oral clearance of HSG4112 (CL/F)
Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112	Hour 0 to 192	Time to maximum observed plasma concentration of HSG4112 (Tmax)
Pharmacokinetic Assessment by Volume of Distribution of HSG4112	Hour 0 to 192	Volume of distribution of HSG4112 (Vd/F)
Safety and Tolerability Assessment by Adverse Event Monitoring	Up to 12 weeks from day of last dosing	Number of participants with observed adverse events
Safety and Tolerability Assessment by Number of Participants with Change in Vital Signs	Up to 3 weeks from day of last dosing	Number of participants with clinically significant change in vital signs including blood pressure (mmHg) measured with blood pressure monitor, heart rate (beats per minute) measured with pulse oximeter, and body temperature (degrees Celcius) measured with thermometer
Safety and Tolerability Assessment by Number of Participants with Change in 12-Lead Electrocardiogram	Up to 3 weeks from day of last dosing	Number of participants with clinically significant change in 12-lead electrocardiogram

Secondary Outcome Measures

Name	Time	Method
Pharmacodynamic Assessment by Change of Biomarkers	Day 1 and 14 pre-dose	Measurement of biomarkers including leptin, adiponectin, insulin, C-peptide (connecting peptide), IL6 (interleukin 6), TNF-alpha (tumor necrosis factor alpha), and CCL2 (C-C motif ligand 2) from baseline to day of last dosing will be combined to assess the weight loss effect of HSG4112

Trial Locations

Locations (2)

Kyungpook National University Hospital; 🇰🇷 Daegu, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of